Company profile for Erytech Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Our mission is to help patients live longer, better. Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encaps...
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Our mission is to help patients live longer, better. Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Erytech Pharma Inc. 1 Main Street, Suite 300 Cambridge, MA 02142
Telephone
Telephone
+1-857-706-1585
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2023/08/08/2720969/0/en/Monthly-information-related-to-total-number-of-voting-rights-and-shares-composing-the-share-capital-_July-31-2023.html

GLOBENEWSWIRE
08 Aug 2023

https://www.globenewswire.com/news-release/2023/07/27/2712677/0/en/PHAXIAM-Therapeutics-announces-a-reverse-share-split-of-its-shares.html

GLOBENEWSWIRE
27 Jul 2023

https://www.globenewswire.com/news-release/2023/06/28/2696600/0/en/Phaxiam-Therapeutics-announces-its-new-mnemonic-code-on-Euronext-and-Nasdaq-PHXM.html

GLOBENEWSWIRE
28 Jun 2023
Meet Phaxiam: Erytech's merger with Pherecydes is complete
Meet Phaxiam: Erytech's merger with Pherecydes is complete

26 Jun 2023

// Max Bayer FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/erytechs-merger-pherecydes-reaches-finish-line-after-contentious-few-months

Max Bayer FIERCE BIOTECH
26 Jun 2023

https://www.globenewswire.com/news-release/2023/06/26/2694839/0/en/ERYTECH-and-PHERECYDES-announce-merger-and-name-change-to-PHAXIAM-Therapeutics.html

GLOBENEWSWIRE
26 Jun 2023

https://www.globenewswire.com/news-release/2023/06/23/2693916/0/en/ERYTECH-announces-the-approval-of-the-merger-with-Pherecydes-and-reports-the-results-of-the-Combined-Shareholder-s-Meeting-held-on-June-23-2023.html

GLOBENEWSWIRE
23 Jun 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty